Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

To gain a better understanding of the role of somatic mutations in olaparib response, next-generation sequencing (NGS) of BRCA1 and BRCA2 was performed as part of a planned retrospective analysis of tumors from a randomized, double-blind, Phase II trial (Study 19; D0810C00019; NCT00753545) in 265 pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Dougherty, Brian A., Lai, Zhongwu, Hodgson, Darren R., Orr, Maria C.M., Hawryluk, Matthew, Sun, James, Yelensky, Roman, Spencer, Stuart K., Robertson, Jane D., Ho, Tony W., Fielding, Anitra, Ledermann, Jonathan A., Barrett, J. Carl
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2017
Schlagworte:
Priority Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546431/
https://ncbi.nlm.nih.gov/pubmed/28525389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17613
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge